Crossmark

Emerging therapies in Parkinson disease — repurposed drugs and new approaches

Crossref DOI link: https://doi.org/10.1038/s41582-019-0155-7

Published Online: 2019-03-12

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Elkouzi, Ahmad https://orcid.org/0000-0002-4296-5236
Vedam-Mai, Vinata

Eisinger, Robert S. https://orcid.org/0000-0003-3191-2355
Okun, Michael S.
License Information

Text and Data Mining valid from 2019-03-12
More Information

Article History

First Online: 12 March 2019

Competing interests

: V.V.-M. is supported by a grant for the deep brain stimulation brain bank from Abbott. M.S.O. serves as a consultant for the Parkinson's Foundation and has received research grants from NIH, NPF, the Michael J. Fox Foundation, the Parkinson Alliance, the Smallwood Foundation, the Bachmann–Strauss Foundation, the Tourette Syndrome Association and the UF Foundation. M.S.O. has previously received honoraria but in the past >60 months has received no support from industry. M.S.O. has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients and Cambridge (movement disorder books). M.S.O. is an associate editor for the <i>New England Journal of Medicine: Journal Watch Neurology</i>. M.S.O. has participated in continuing medical education and educational activities on movement disorders (in the past 36 months) sponsored by PeerView, Prime, QuantiaMD, WebMD, Medicus, MedNet, Henry Stewart and Vanderbilt University. M.S.O. has participated as a site principal investigator (PI) and/or co-PI for several NIH, foundation and industry-sponsored trials over the years but has not received honoraria. A.E. and R.S.E. have no competing interests.